Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis

References

• Centers for Disease, C. and Prevention, Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001–2009. MMWR Morb Mortal Wkly Rep 2011;60(17):547–552.
   PubMedGoogle Scholar
• Moore WC, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007;119(2):405–413.
   PubMed Web of Science ®Google Scholar
• Chung KF, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43(2):343–373.
   PubMed Web of Science ®Google Scholar
• Presta L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994;269(42):26368–26373.
   PubMed Web of Science ®Google Scholar
• Milgrom H, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999;341(26):1966–1973.
   Google Scholar
• Bousquet J, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125(4):1378–1386.
   PubMed Web of Science ®Google Scholar
• Rothenberg ME and Hogan SP. The eosinophil. Annu Rev Immunol 2006;24:147–174.
   PubMed Web of Science ®Google Scholar
• Green RH, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360(9347):1715–1721.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160(3):1001–1008.
   PubMed Web of Science ®Google Scholar
• Bel EH, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Haldar P, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360(10):973–984.
   PubMed Web of Science ®Google Scholar
• Ortega HG, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Pavord ID, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• Nair P, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360(10):985–993.
   PubMed Web of Science ®Google Scholar
• Moher D, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
   PubMed Web of Science ®Google Scholar
• Ayres JG, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59(7):701–708.
   PubMed Web of Science ®Google Scholar
• Bardelas J, et al. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma 2012;49(2):144–152.
   PubMed Web of Science ®Google Scholar
• Bousquet J, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011;66(5):671–678.
   PubMed Web of Science ®Google Scholar
• Buhl R, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20(5):1088–1094.
   PubMed Web of Science ®Google Scholar
• Buhl R, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20(1):73–78.
   PubMed Web of Science ®Google Scholar
• Busse W, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184–190.
   PubMed Web of Science ®Google Scholar
• Finn A, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003;111(2):278–284.
   PubMed Web of Science ®Google Scholar
• Garcia G, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 2013;144(2):411–419.
   PubMed Web of Science ®Google Scholar
• Hanania NA, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154(9):573–582.
   PubMed Web of Science ®Google Scholar
• Holgate ST, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34(4):632–638.
   PubMed Web of Science ®Google Scholar
• Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration 2012;83(6):520–528.
   PubMed Web of Science ®Google Scholar
• Humbert M, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309–316.
   PubMed Web of Science ®Google Scholar
• Niven R, et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008;102(10):1371–1378.
   PubMed Web of Science ®Google Scholar
• Ohta K, et al. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology 2009;14(8):1156–1165.
   PubMed Web of Science ®Google Scholar
• Rubin AS, et al. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma 2012;49(3):288–293.
   PubMed Web of Science ®Google Scholar
• Soler M, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18(2):254–261.
   PubMed Web of Science ®Google Scholar
• Vignola AM, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59(7):709–717.
   PubMed Web of Science ®Google Scholar
• Wittchen HU, et al. Omalizumab versus ‘usual care’: results from a naturalistic longitudinal study in routine care. Int Arch Allergy Immunol 2012;159(1):83–93.
   PubMed Web of Science ®Google Scholar
• Flood-Page P, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176(11):1062–1071.
   PubMed Web of Science ®Google Scholar